IoNIR Ridaforolimus-Eluting Coronary Stent System
Asset
Releases ridaforolimus to inhibit MTOR and vascular smooth muscle proliferation, limiting restenosis while supporting the coronary artery.
- Stage
- Human trials
- Modality
- Device
- Target
- mTOR signalling
- 2
- Indications
- 1
- Trial
- 1
- Developer
Indications
2Coronary artery disease
Human trials, Suspended, NCT06071702, clinicaltrials.gov, 13 Oct 2026
Coronary stenosis
Human trials, Suspended, NCT06071702, clinicaltrials.gov, 13 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets2
- Competitors2
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.